Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Elisavet, Serti"'
Autor:
Erin M. Witkop, Kirsten Diggins, Alice Wiedeman, Elisavet Serti, Gerald Nepom, Vivian H. Gersuk, Bryce Fuchs, S. Alice Long, Peter S. Linsley
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-14 (2024)
Abstract Distinct Natural Killer (NK)-like CD57+ and PD-1+ CD8+ exhausted-like T cell populations (Tex) have both been linked to beneficial immunotherapy response in autoimmune type 1 diabetes (T1D) patients. The origins and relationships between the
Externí odkaz:
https://doaj.org/article/8d3fb1a37da44494b3b4cd1c67e7d55e
Autor:
Peter S. Linsley, Maki Nakayama, Elisa Balmas, Janice Chen, Fariba Barahmand-pour-Whitman, Shubham Bansal, Ty Bottorff, Elisavet Serti, Cate Speake, Alberto Pugliese, Karen Cerosaletti
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Human type 1 diabetes (T1D) is caused by autoimmune attack on the insulin-producing pancreatic beta cells by islet antigen-reactive T cells. How human islet antigen-reactive (IAR) CD4+ memory T cells from peripheral blood affect T1D progress
Externí odkaz:
https://doaj.org/article/66f2c80699f6498b86e42acf78ab840a
Autor:
Elisa Balmas, Janice Chen, Alex K. Hu, Hannah A. DeBerg, Mario G. Rosasco, Vivian H. Gersuk, Elisavet Serti, Cate Speake, Carla J. Greenbaum, Gerald T. Nepom, Peter S. Linsley, Karen Cerosaletti
Publikováno v:
JCI Insight, Vol 8, Iss 21 (2023)
Variation in the preservation of β cell function in clinical trials in type 1 diabetes (T1D) has emphasized the need to define biomarkers to predict treatment response. The T1DAL trial targeted T cells with alefacept (LFA-3–Ig) and demonstrated C-
Externí odkaz:
https://doaj.org/article/fc5124fb6eab4bc1a3e7082177f0b113
Autor:
Carla J. Greenbaum, Elisavet Serti, Katharina Lambert, Lia J. Weiner, Sai Kanaparthi, Sandra Lord, Stephen E. Gitelman, Darrell M. Wilson, Jason L. Gaglia, Kurt J. Griffin, William E. Russell, Philip Raskin, Antoinette Moran, Steven M. Willi, Eva Tsalikian, Linda A. DiMeglio, Kevan C. Herold, Wayne V. Moore, Robin Goland, Mark Harris, Maria E. Craig, Desmond A. Schatz, David A. Baidal, Henry Rodriguez, Kristina M. Utzschneider, Hendrik J. Nel, Carol L. Soppe, Karen D. Boyle, Karen Cerosaletti, Lynette Keyes-Elstein, S. Alice Long, Ranjeny Thomas, James G. McNamara, Jane H. Buckner, Srinath Sanda, for the ITN058AI EXTEND Study Team
Publikováno v:
JCI Insight, Vol 6, Iss 21 (2021)
Background IL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in
Externí odkaz:
https://doaj.org/article/083a57294536479793c92cf07ad43e13
Autor:
Peter S. Linsley, Fariba Barahmand-pour-Whitman, Elisa Balmas, Hannah A. DeBerg, Kaitlin J. Flynn, Alex K. Hu, Mario G. Rosasco, Janice Chen, Colin O’Rourke, Elisavet Serti, Vivian H. Gersuk, Keshav Motwani, Howard R. Seay, Todd M. Brusko, William W. Kwok, Cate Speake, Carla J. Greenbaum, Gerald T. Nepom, Karen Cerosaletti
Publikováno v:
JCI Insight, Vol 6, Iss 22 (2021)
Human islet antigen reactive CD4+ memory T cells (IAR T cells) play a key role in the pathogenesis of autoimmune type 1 diabetes (T1D). Using single-cell RNA sequencing (scRNA-Seq) to identify T cell receptors (TCRs) in IAR T cells, we have identifie
Externí odkaz:
https://doaj.org/article/ae78e844c0644847af1e433a33d6fd7d
Autor:
Ephraim L Tsalik, Nadine G Rouphael, Ruxana T Sadikot, Maria C Rodriguez-Barradas, Micah T McClain, Dana M Wilkins, Christopher W Woods, Geeta K Swamy, Emmanuel B Walter, Hana M El Sahly, Wendy A Keitel, Mark J Mulligan, Bonifride Tuyishimire, Elisavet Serti, Toshimitsu Hamasaki, Scott R Evans, Varduhi Ghazaryan, Marina S Lee, Ebbing Lautenbach, Ghina Alaaeddine, Jennifer J. Zreloff, Nina McNair, Colleen S. Kraft, David L. Roberts, Sharon H. Bergquist, Nour Beydoun, Jesse J. Waggoner, Merin E. Kalangara, Matthew H. Collins, Alexandra W. Dretler, Amer R. Bechnak, Laura Oh, Zhihong Yuan, Brian J. Burrows, Emily R. Ko, Weixiao Dai, Lijuan Zeng
Publikováno v:
The Lancet Infectious Diseases. 23:484-495
Lower respiratory tract infections are frequently treated with antibiotics, despite a viral cause in many cases. It remains unknown whether low procalcitonin concentrations can identify patients with lower respiratory tract infection who are unlikely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6174b981eb3a53b96ead7e537e6ea0d
https://doi.org/10.1016/s1473-3099(22)00735-6
https://doi.org/10.1016/s1473-3099(22)00735-6
Autor:
Kirsten E. Diggins, Elisavet Serti, Virginia Muir, Mario Rosasco, TingTing Lu, Elisa Balmas, Gerald Nepom, S. Alice Long, Peter S. Linsley
Publikováno v:
JCI Insight, Vol 6, Iss 3 (2021)
Clinical trials of biologic therapies in type 1 diabetes (T1D) aim to mitigate autoimmune destruction of pancreatic β cells through immune perturbation and serve as resources to elucidate immunological mechanisms in health and disease. In the T1DAL
Externí odkaz:
https://doaj.org/article/37b23ff4286140899c19dfc035864cd1
Autor:
Aditi Narsale, Breanna Lam, Rosa Moya, TingTing Lu, Alessandra Mandelli, Irene Gotuzzo, Benedetta Pessina, Gianmaria Giamporcaro, Rhonda Geoffrey, Kerry Buchanan, Mark Harris, Anne-Sophie Bergot, Ranjeny Thomas, Martin J. Hessner, Manuela Battaglia, Elisavet Serti, Joanna D. Davies
Publikováno v:
JCI Insight, Vol 6, Iss 2 (2021)
Transient partial remission, a period of low insulin requirement experienced by most patients soon after diagnosis, has been associated with mechanisms of immune regulation. A better understanding of such natural mechanisms of immune regulation might
Externí odkaz:
https://doaj.org/article/20ba8c4ce6b4454ea7c69dca229e3557
Autor:
Thomas P, Lodise, J Nicholas, O'Donnell, Shruti, Raja, Jeffrey T, Guptill, Smitha, Zaharoff, Nyssa, Schwager, Vance G, Fowler, Tatiana, Beresnev, Alison, Wall, Katherine, Wiegand, Elisavet, Serti Chrisos, Stephen, Balevic, Henry F, Chambers
Publikováno v:
Antimicrob Agents Chemother
This phase I study evaluated the safety of the optimal ceftazidime-avibactam (CZA) with aztreonam (ATM) regimens identified in hollow fiber infection models of MBL-producing Enterobacterales. Eligible healthy subjects aged 18 to 45 years were assigne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c02371d0a1b9781145ed4ccbb58f6815
https://doi.org/10.1128/aac.00935-22
https://doi.org/10.1128/aac.00935-22
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.